Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Michael Matthews (Jayco-AlUla) powered to his third victory in the Grand Prix de Québec, out-sprinting Biniam Girmay ...

WeightWatchers is remaking itself to appeal to both dieters and weight-loss medication users. But have consumers already lost ...

In a late-stage clinical trial, a drug similar to Ozempic was shown to reduce body mass index in kids ages 6 to 11 with ...

Novo Nordisk A/S has exercised an option to license a ligand identified by Kallyope Inc. for further development, including as a potential new approach for the treatment of obesity.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, ...